- •
The diagnosis and treatment of Chagas disease require specific knowledge about the acute and chronic forms of the disease.
- •
The initial Chagas infection is typically asymptomatic but after a decade or longer, approximately 30% of people will progress to a chronic cardiac form of Chagas cardiomyopathy with symptoms including heart failure, arrhythmias, and thromboembolism.
- •
Death is often premature and sudden due to arrhythmias or progressive heart failure.
- •
Prevention of infection through vector
Chagas Cardiomyopathy: Clinical Presentation and Management in the Americas
Section snippets
Key points
Epidemiology
Chagas disease is a disease of poverty. It is on the World Health Organization’s (WHO) list of 17 neglected tropical diseases because it shares similar characteristics, such as particular geographic dispersion affecting populations with poor socioeconomic status; high morbidity and consequent mortality with significant socioeconomic impact; biomedical and psychosocial barriers to diagnosis, treatment, and control; and limited availability of resources and political priority. It is endemic to
Pathogenesis
The pathogenesis of Chagas heart disease involves a complex interaction of different processes (Fig. 2),17 related to tissue damage due to parasite persistence, inflammation, autoimmunity, fibrosis, dysautonomia, and microvascular changes.18, 19 After the acute, febrile phase, the T cruzi parasite hides in target tissues (namely the cardiac and digestive system muscles) and enters the chronic phase, almost always without clinical manifestations. However, a low-grade inflammation persists during
Clinical aspects of Chagas disease
Chagas disease presents classically as 2 different phases: acute and chronic. Each phase has different clinical characteristics, diagnostic criteria, and treatment. The most common symptoms in the various Chagas disease phases are listed in Table 1.
Diagnosis
The diagnosis of acute Chagas disease is made by the detection of the parasite in blood samples or by seroconversion. Enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF), indirect hemagglutination (IHA) test, and parasite polymerase chain reaction (PCR) are the most widely available tests. There are also rapid diagnostic tests that can directly detect the causative parasite, T cruzi.60 In the chronic phase, the parasitemia burden is lower and diagnosis often requires
Treatment
Treatment during the acute phase is recommended and associated with a near 100% cure rate with antitrypanosomal therapy.61 Currently available regimens include benznidazole and nifurtimox. Benznidazole 5 mg/kg per day (maximum 300 mg/24 hours) is given in 2 to 3 divided daily oral doses for 60 days in chronic cases (10 mg/kg per day in acute cases). In children younger than 12 years, the recommended dose is 8 to 10 mg/kg per day in 3 to 4 daily oral doses for 60 days. The side effect of
Prevention
Despite the enormous benefit of preventive therapy on the control of many neglected tropical diseases, unfortunately it does not work for Chagas disease. The most effective approaches are vector control programs in endemic areas, which require retaining political interest, public health resources, and financial commitments, as well as active surveillance and control programs. For nonvectoral transmission, maintaining universal screening for blood donors and organ transplantation donors and
Prognosis
Deaths are rare in the acute phase and most deaths attributable to Chagas disease result from downstream cardiovascular sequelae. Sudden death accounts for approximately 55% to 65% of deaths in patients with chronic Chagas and is likely underestimated due to underreporting, particularly in rural areas.13 It is more common in those with severe underlying heart disease and is precipitated by intense exercise. The main causes are VT or ventricular fibrillation, complete atrioventricular block, or
Summary
Chagas cardiomyopathy is a chronic condition and remains a significant cause of morbidity and mortality in Latin America. The diagnosis and treatment require specific knowledge about the acute and chronic forms of the disease. Chronic Chagas cardiomyopathy manifests as disorders of the heart’s conduction system, heart failure, or pulmonary or cerebrovascular embolisms, leading to premature mortality and perpetuates the cycle of poverty in those affected. A strong surveillance system is required
References (98)
- et al.
Chagas disease: a Latin American health problem becoming a world health problem
Acta Trop
(2010) Evolution of Chagas disease screening programs and control programs: historical perspective
Glob Heart
(2015)- et al.
Chagas disease in Spain, the United States and other non-endemic countries
Acta Trop
(2010) - et al.
The burden of Chagas disease
Glob Heart
(2015) - et al.
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition
Lancet
(2015) - et al.
Global economic burden of Chagas disease: a computational simulation model
Lancet Infect Dis
(2013) - et al.
Autoimmunity
Adv Parasitol
(2011) - et al.
The Valsalva maneuver in Chagas disease patients without cardiopathy
Int J Control
(2002) - et al.
Vagal dysfunction in Chagas disease
Int J Control
(2005) - et al.
Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas' disease
Int J Cardiol
(1998)
The prognostic significance of electrocardiographic changes in Chagas disease
J Electrocardiol
Chagas disease: an overview of clinical and epidemiological aspects
J Am Coll Cardiol
Electrocardiogram and Chagas disease: a large population database of primary care patients
Glob Heart
Ventricular tachycardia in Chagas' disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms
Int J Control
Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study
J Neurol Sci
Rapid Chagas diagnosis in clinical settings using a multiparametric assay
Diagn Microbiol Infect Dis
Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up
Am Heart J
The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology
Ann Thorac Surg
Control of Chagas disease
Adv Parasitol
Clinical predictors of chronic chagasic myocarditis progression
Rev Esp Cardiol
Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy
Int J Cardiol
Left atrial volume provides independent prognostic value in patients with Chagas cardiomyopathy
J Am Soc Echocardiogr
Mortality indicators among chronic Chagas patients living in an endemic area
Int J Cardiol
Effects of B-Blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure
Int J Cardiol
Different prognostic impact of the tissue Doppler-derived E/e' ratio on mortality in Chagas cardiomyopathy patients with heart failure
J Heart Lung Transplant
Nova trypanozomiaze humana
Mem Inst Oswaldo Cruz
American trypanosomiasis (Chagas' disease)–a tropical disease now in the United States
N Engl J Med
Epidemiology of Chagas disease in non-endemic countries: the role of international migration
Mem Inst Oswaldo Cruz
Chagas disease: “the new HIV/AIDS of the Americas”
PLoS Negl Trop Dis
Oral transmission of Chagas disease
Clin Infect Dis
Control of Chagas disease: second report of a WHO expert committee
Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis
Chagas disease in Latin America: an epidemiological update based on 2010 estimates
Wkly Epidemiol Rec
American trypanosomiasis: epidemiology and risk factors
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Lancet
Chagas heart disease pathogenesis: one mechanism or many?
Curr Mol Med
Developments in the management of Chagas cardiomyopathy
Expert Rev Cardiovasc Ther
Pathogenesis of chronic Chagas heart disease
Circulation
Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity
Eur J Heart Fail
Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic Chagas heart disease
Am J Trop Med Hyg
Parasite persistence correlates with disease severity and localization in chronic Chagas' disease
J Infect Dis
Pathogenesis of Chagas cardiomyopathy: role of inflammation and oxidative stress
J Am Heart Assoc
Pathogenesis of Chagas disease: time to move on
Front Biosci (Elite Ed)
Immunoregulatory networks in human Chagas disease
Parasite Immunol
Cardiac autonomic dysfunction and neuroganglionitis in a rat model of chronic Chagas' disease
Cardiovasc Radiol
Sustained ventricular tachycardia is associated with regional myocardial sympathetic denervation assessed with 123I-metaiodobenzylguanidine in chronic Chagas cardiomyopathy
J Nucl Med
Pathogenesis of chronic Chagas cardiomyopathy: the role of coronary microvascular derangements
Rev Soc Bras Med Trop
Indeterminate form of Chagas disease: considerations about diagnosis and prognosis
Rev Soc Bras Med Trop
Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy
Arq Bras Cardiol
Cited by (59)
Cardiovascular Complications of Chagas' Disease
2022, The NET-Heart Book: Neglected Tropical Diseases and other Infectious Diseases affecting the HeartChagas Disease: Chronic Chagas Cardiomyopathy
2021, Current Problems in CardiologyCitation Excerpt :CD is asymptomatic in the vast majority of patients during the acute phase, but chronic infection will manifest as a multisystem disease affecting mainly the cardiovascular and digestive systems. Chagas cardiomyopathy is the leading cause of nonischemic cardiomyopathy (NICM) in Latin America and affects around 30% of infected patients.1,2 The foremost characteristics are a diffuse myocarditis with focal fibrosis, mainly located in the apex and basal segments of the posterior and inferior wall, as well as left ventricular hypertrophy.
Assessment of biomarkers and clinical parameters as predictors of survival in patients with chagasic heart failure
2023, PLoS Neglected Tropical DiseasesIntestinal permeability evaluation in patients with chronic Chagas heart failure
2023, ESC Heart Failure
Disclosures: The authors have nothing to disclose.